Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TITAN-TCC phase II trial of nivolumab-based tailored immunotherapy in advanced or metastatic transitional cell carcinoma
2016-004857-33Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in transitional cell carcinoma (TCC), Renal pelvis urothelial carcinoma (UTUC) and ureteral urothelial carcinoma, sponsored by AIO-Studien. Primary endpoint: Overall response rate. Started Feb 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
transitional cell carcinoma (TCC)Renal pelvis urothelial carcinoma (UTUC)ureteral urothelial carcinoma
Beyond the preview
Go deeper on 2016-004857-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004857-33.